Stockreport

ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia treatment [Yahoo! Finance]

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF NewAmsterdam has shown promising data in all Phase II trials, ROSE2, TULIP, ROSE, and OCEAN, evaluating obicetrapib as a monotherapy or combination therapy, with the abi [Read more]